Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Atrasentan in Patients With Proteinuric Glomerular Diseases

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

  • 0 views
  • 09 May, 2021
  • 9 locations
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes

Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney. These drugs also improve body weight, blood pressure, and cardiac function. Based on these …

diabetes
hemoglobin a1c
blood sugar
body mass index
  • 72 views
  • 25 Jan, 2021
  • 1 location
Efficacy and Safety of Dapagliflozin in Acute Heart Failure

This is a randomized trial of the addition of dapagliflozin to patients with diabetes hospitalized with acute decompensated heart failure (ADHF). Participants will be recruited following an initial standard evaluation in the ED and randomized within 24 hours of presentation for ADHF in a 1:1 fashion to protocolized diuretic therapy …

loop diuretic
decompensated heart failure
dyspnea
edema
diabetes
  • 55 views
  • 24 Jan, 2021
  • 3 locations
Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

The Investigator hypothesize that Dapagliflozin will improve EPC number and function AND Saxagliptin in addition to Dapagliflozin (additive effect) may improve EPC number and function even more than Dapa alone, compared to placebo. The Investigator propose a 3-arm randomized, parallel group, longitudinal study of 16-week intervention duration. Participants will be …

saxagliptin
diabetes
stroke
angina pectoris
metformin
  • 15 views
  • 25 Jan, 2021
  • 1 location
Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors

To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac magnetic resonance imaging (MRI) and (ii) myocardial glucose uptake using positron emission tomography (PET) …

nt-probnp
sglt2 inhibitor
diabetes
sglt2
MRI
  • 106 views
  • 24 Jan, 2021
  • 2 locations
HF Prevalence and Evolution of HF in DM II Patients at High Risk

This is an epidemiological, single-country, multicenter, 2-year prospective cohort study based on both primary and secondary data collection, which will include a representative sample of 300 eligible T2DM patients managed in real-life settings in Greece. A cross-sectional approach will be applied for addressing the primary objective of the study (prevalence …

  • 0 views
  • 01 May, 2021
  • 10 locations